Novavax (NVAX) Total Liabilities (2010 - 2026)

Novavax's Total Liabilities history runs 17 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• On a quarterly basis, Total Liabilities fell 13.2% year-over-year to $1.2 billion in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 13.2% decrease from a year earlier, with the FY2025 full-year figure at $1.3 billion, down 40.29% from the prior year.
• Total Liabilities fell to $1.2 billion in Q1 2026 per NVAX's latest filing, from $1.3 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $3.0 billion in Q2 2022 and bottomed at $1.2 billion in Q1 2026.
• The 5-year median for Total Liabilities is $2.3 billion (2024), against an average of $2.2 billion.
• Across the five-year window, Total Liabilities surged 76.49% in 2022 and tumbled 42.28% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $2.9 billion in 2022, then fell by 13.08% to $2.5 billion in 2023, then dropped by 13.13% to $2.2 billion in 2024, then tumbled by 40.29% to $1.3 billion in 2025, then fell by 8.92% to $1.2 billion in 2026.
• Per Business Quant, the three latest NVAX Total Liabilities figures stand at $1.2 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.3 billion (Q3 2025).